Karyopharm Therapeutics Announces Initiation Of An Investigator Sponsored Phase 1 Dose Escalation Study Of Its Lead Drug Candidate Selinexor (KPT-330) In Singapore

Published: Feb 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 study of oral Selinexor in Asian patients with advanced or metastatic solid tumors. Selinexor (KPT-330), is a first-in-class, oral Selective Inhibitors of Nuclear Export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus and the selective induction of apoptosis in cancer cells. This study is designed to determine the recommended Phase 2 dose and assess the safety and preliminary evidence of anti-cancer activity in Asian patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news